• Mianserin HCl: Applied Research Workflows

  2026-08-28

  Mianserin HCl supports controlled studies of 5-HT2 receptor signaling, time-dependent phenotypes, and cyclodextrin-enabled exposure. This guide translates clinical pharmacology findings into practical workflows for neuroscience, cytotoxicity, and antipathogenic research while emphasizing formulation controls and assay-specific troubleshooting.

• ECL Western Blotting Substrate: Practical Guide

  2026-08-28

  ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive reagent for detecting HRP on immunoblots with X-ray film or CCD imaging. It is intended for HRP-based Western blot workflows and should not be used as a substitute for fluorescent or radioisotopic detection methods.

• Fzd5 Links Cholesterol to Wnt Signaling in Cancer

  2026-08-27

  The reference study identifies Frizzled5 (Fzd5) as a cholesterol-sensitive Wnt receptor that connects abnormal lipid metabolism with β-catenin signaling in pancreatic ductal adenocarcinoma. Its findings suggest that cholesterol-dependent receptor maturation and palmitoylation, rather than ligand binding alone, can determine Wnt pathway activity and tumor growth.

• Rotigotine: Dopamine D2/D3 Agonist Research Guide

  2026-08-27

  Rotigotine is a dopamine D2/D3 receptor agonist and dopaminergic signaling pathway modulator used in Parkinson’s disease research. Published rat studies show antidepressant-like activity in forced-swim, learned-helplessness, and olfactory-bulbectomy models, while higher doses can confound behavioral interpretation through increased locomotion.

• Doxycycline hyclate for MMP-2/MMP-9 BBB Research

  2026-08-26

  Doxycycline hyclate functions as a practical matrix metalloproteinases inhibitor for connecting MMP activity with blood-brain barrier failure, neuronal apoptosis, and cognitive phenotypes. This workflow translates an arsenic neurotoxicity study into reproducible formulation, assay-selection, and troubleshooting strategies for neurovascular and intracranial aneurysm research.

• mTORC1 Oscillation Controls Cell-Cycle Transitions

  2026-08-26

  The reference study demonstrates that mTORC1 activity is not constant during proliferation but oscillates between low activity in mitosis and G1 and high activity in S and G2. These phase-specific changes help coordinate interphase progression, G2/M checkpoint satisfaction, and differential sensitivity to autophagy induction.

• BMS 309403: Reliable FABP4 Assay Design

  2026-08-25

  Learn how BMS 309403 (SKU B7794) can support reproducible cell viability, inflammatory, lipid-accumulation, and cytotoxicity workflows. This scenario-based guide connects FABP4 biology with practical concentration selection, vehicle control, endpoint interpretation, and vendor evaluation.

• SARS-CoV-2 N Protein, GADD34, and Innate Immunity

  2026-08-25

  The 2024 Molecules study identifies an atypical stress-granule mechanism by which SARS-CoV-2 nucleocapsid protein suppresses GADD34-dependent innate immunity. Its findings connect GADD34 mRNA sequestration in N+/G3BP1+ foci with impaired IRF3 nuclear localization, providing a mechanistic framework for viral immune evasion and for designing assays that distinguish condensate formation from productive antiviral signaling.

• Bortezomib (PS-341) Experimental Workflows

  2026-08-24

  Bortezomib (PS-341) offers reversible 20S proteasome inhibition for controlled apoptosis assays, cancer-cell profiling, and mechanistic studies of proteostasis. This workflow-focused guide also explains how to use PS-341 as a comparator when investigating the proteasome–ER stress–FOXN1 axis reported in thymic epithelial cells.

• Foretinib Workflows for Cancer Drug Response

  2026-08-23

  Build more informative cancer assays with Foretinib by separating tumor cell growth inhibition from cell death and motility effects. This workflow combines dose–time optimization, orthogonal readouts, and translational model selection for reproducible multikinase research.

• BODIPY 581/591 C11 for Lipid Peroxidation

  2026-08-22

  Use BODIPY 581/591 C11 as a ratiometric fluorescent probe to quantify membrane oxidation in live cells, model membranes, and cardiovascular injury workflows. Its red-to-green shift supports antioxidant capacity evaluation while distinguishing lipid oxidation from broad, nonspecific ROS signals.

• Drug Response Metrics in Cancer Beyond Viability

  2026-08-21

  Hannah Schwartz’s dissertation shows why a single viability endpoint can obscure the distinction between proliferation arrest and true cell killing. Its central contribution is a comparative framework that separates relative viability from fractional viability and emphasizes their different magnitudes and time courses, improving interpretation of anticancer drug responses in vitro.

• EdU Cell Proliferation Kit for RA S-Phase Studies

  2026-08-20

  Turn DNA synthesis into a sensitive, non-radioactive TMB signal for direct S-phase analysis in rheumatoid arthritis fibroblast-like synoviocytes. This workflow connects ARL4C perturbation studies with practical cell proliferation measurement, genotoxicity testing, and pharmacodynamic drug evaluation.

• Perphenazine: From D2 Antagonism to Host Defense

  2026-08-20

  Perphenazine is more than a conventional neuropharmacology tool. Its dopamine D2 receptor antagonism, broader phenothiazine receptor-binding profile, mitochondria-mediated cell death induction, and emerging host-directed antibacterial activity create a translational framework for connecting neuronal signaling, cellular stress, and innate immunity. This article examines how researchers can use Perphenazine to build mechanism-focused workflows while maintaining appropriate boundaries between established evidence and exploratory application.

• Methicillin Sodium Salt: From Benchmark to Strategy

  2026-08-19

  Methicillin sodium salt remains more than a historical antibiotic: it is a mechanistic benchmark for MSSA biology, resistance-aware assay design, and translational decision-making. This article connects PBP-mediated cell-wall inhibition with modern antibacterial development, using the 2025 EAGLE-1 gepotidacin study to clarify what can—and cannot—be extrapolated across pathogens.

445 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page